MedTrace Logo

Study to Assess Effects of Postbiotic vs Placebo in Participants With Diarrhea-predominant IBS

NCT06346847 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 384

Last updated 2026-03-23

No results posted yet for this study

Summary

The present study is a randomized, double-blind, placebo-controlled, parallel group clinical study that assesses the effect of postbioc on the complaints of subjects with moderate to severe diarrhoea-predominant irritable bowel syndrome (IBS-D). The trial is also evaluating the potential of postbiotic on anxiety, low mood and stress of the participants, as well as its safety and tolerability.

The intervention duration for all the study participants is 12 weeks (intervention phase). Subsequently, the participants will be invited to return to site for an end of study assessment after 21 days of no intervention (post-intervention phase).

Conditions

  • Diarrhea-Predominant Irritable Bowel Syndrome

Interventions

DIETARY_SUPPLEMENT

Postbiotic

1 capsule a day, 15 minutes before breakfast with a glass of water for 12 weeks

DIETARY_SUPPLEMENT

Placebo

1 capsule a day, 15 minutes before breakfast with a glass of water for 12 weeks

Sponsors & Collaborators

  • Vedic Lifesciences Pvt. Ltd.

    collaborator INDUSTRY

  • A-Mansia Biotech S.A.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-18
Primary Completion
2025-05-29
Completion
2025-07-13

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06346847 on ClinicalTrials.gov